Fig. 1 · Structure

Documents & Downloads

Tanshinone IIA (Tanshinone B)

Cat. No. A10890 CAS 568-72-9
Tanshinone IIA (TIIA) is one of the major extracts obtained from Salvia miltiorrhiza BUNGE, which has anti-inflammatory and anti-apoptotic effects on many diseases.

In Stock

Publications for Tanshinone IIA

3 publications citing this product

  1. Qiwen Yan, .et al. , Regen Ther, 2023, Dec; 24: 417-425 PMID: 37727797
  2. Judith Schaf, .et al. , Cell Death Discov, 2023, May 19;9(1):172 PMID: 37202382
  3. Williams R, .et al. , Research Square, 2022, NOV 21

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Tanshinone IIA inhibited stimulated PIP3 production in a Dictyostelium cellular reporter assay, with a reported acute IC50 of 1.57 µM. This readout supports suppression of PI3K-associated signaling under the tested conditions; it does not establish direct enzyme binding or isoform selectivity. [1]

Tanshinone IIA cytotoxicity depended on cellular context: NQO1-negative H596 cells were less sensitive than A549 cells, and pharmacological inhibition or knockdown of NQO1 attenuated the A549 response. p53 inhibition or knockdown had little effect in this experiment. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 2.2 μM Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay [PMID: 34333396]
A549 IC50 53.2 μM Antiproliferative activity against human A549 cells after 72 hrs by MTT assay [PMID: 30398868]
A549 IC50 6.68 μM Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by cell titer glo luminescent assay [PMID: 35640078]
AGS IC50 10 μM Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay [PMID: 17583950]
AGS IC50 6.8 μM Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay [PMID: 17583950]
AGS IC50 7.53 μM Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay [PMID: 17583950]
BGC-823 IC50 2.8 μM Anticancer activity against human BGC-823 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay [PMID: 36332549]
CWR22R IC50 6.7 μM Cytotoxicity against human 22Rv1 cells incubated for 72 hrs by MTT assay [PMID: 22175694]
HeLa IC50 193.2 μM Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay [PMID: 30398868]
HeLa IC50 3.47 μM Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay [PMID: 34333396]
Hep 3B2 IC50 > 50 μM Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay [PMID: 17583950]
Hep 3B2 IC50 > 50 μM Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay [PMID: 17583950]
Hep 3B2 IC50 6.18 μM Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay [PMID: 17583950]
HepG2 IC50 23.85 μM Antiproliferative activity against human HepG2 cells by MTT assay [PMID: 33601313]
HepG2 IC50 4.91 μM Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay [PMID: 34333396]
HepG2 IC50 65.7 μM Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay [PMID: 30398868]
L02 IC50 65.29 μM Antiproliferative activity against human L02 cells by MTT assay [PMID: 33601313]
L02 IC50 78.5 μM Antiproliferative activity against human L02 cells after 72 hrs by MTT assay [PMID: 30398868]
LNCaP IC50 0.5 μM Cytotoxicity against human LNCAP cells incubated for 72 hrs by MTT assay [PMID: 22175694]
LNCaP C4-2B IC50 0.4 μM Cytotoxicity against human C4-2B cells incubated for 72 hrs by MTT assay [PMID: 22175694]

20 records · Scroll to view more

Tanshinone IIA (Tanshinone B) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Tanshinone IIA (Tanshinone B) from 2 published references. In vitro models include dictyostelium discoideum Ax3 cells expressing PHCrac-GFP; patient-derived human GBM59 cells grown as 3D spheroids.

Tanshinone IIA (Tanshinone B) In Vitro Studies

In a 72-h MTT assay, tanshinone IIA had a reported IC50 of 5.32 µM in A549 cells and >40 µM in NQO1-negative H596 cells. These are model-specific metabolic-viability endpoints, not treatment doses or universal potency values. [2]

In human GBM59 spheroids, tanshinone IIA (3.77 µM) combined with Paxalisib (0.46 µM) enhanced growth inhibition relative to Paxalisib alone over nine days. The high-dose combination reduced volume below its starting value. This combination result does not establish a single-agent clinical effect. [1]

Cellular PIP3 response in Dictyostelium

Cell-based study · Dictyostelium discoideum Ax3 cells expressing PHCrac-GFP [1]

T2A suppressed cAMP-stimulated PHCrac-GFP membrane recruitment, a cellular readout of PIP3 production. The reported acute IC50 was 1.57 µM. Solvent and LY294002 controls support assay interpretation; this is not a purified PI3K enzyme assay or a direct binding measurement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of stimulated PIP3-associated membrane recruitmentCellular IC50 1.57 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
T2A 0–25 µM (acute concentration response); 25 µM (4-h comparison)
Exposure duration
15 min for acute concentration response; 4 h for prolonged comparison
Method
PHCrac-GFP membrane translocation after cAMP stimulation; comparison with solvent and LY294002
Vehicle
0.2% DMSO
Co-treatment
LY294002 comparator; combination responses not adopted
Reported limits
No purified-enzyme potency or PI3K isoform selectivity established in this assay.
Methods and source locations

Compound reported in the paper: Tanshinone IIA; Compound label in the paper: T2A

Experimental findings for the reported parent compound and tested material; no validation of the current AdooQ lot or human efficacy.

Results Sec4; Fig. 2B–F; Methods Sec13, Sec16; SI captions S1–S2

Inhibition of stimulated PIP3-associated membrane recruitment: PHCrac-GFP fluorescence assay; 15-min treatment; mean ± SEM; Fig. 2 caption reports at least N = 6, three independently stimulated cells per experiment (technical observations are not additional biological replicates). — Results Sec4; Fig. 2E–F; Methods Sec16

Tanshinone IIA with Paxalisib in human GBM59 spheroids

Cell-based study · Patient-derived human GBM59 cells grown as 3D spheroids [1]

At T2A 3.77 µM and Paxalisib 0.46 µM, the combination reduced spheroid growth more than Paxalisib alone. The high-dose combination produced regression relative to starting volume at day 9. Single-agent, combination and solvent groups were compared in the same design. Not an animal experiment or clinical response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Spheroid volume change at day 9Direction versus comparator Enhanced growth inhibition with combination versus Paxalisib alone; high-dose combination regressed below starting volume[1]

Literature-Reported Treatment Conditions

Treatment concentration
T2A 3.77 µM; Paxalisib 0.46 µM
Exposure duration
9 days; size assessed before treatment and on days 3, 6 and 9
Method
Microscopy with ImageJ; spherical volume estimated from spheroid size
Vehicle
Solvent-only control; spheroid solvent identity/final percentage not specified in this method
Co-treatment
Paxalisib 0.46 µM; both single-agent comparators included
Reported limits
No exact volume estimated from plotted curves; no Bliss synergy claim adopted; no GL261 timing assumption. Seeding statement and monolayer doses are not adopted as spheroid conditions.
Methods and source locations

Compound reported in the paper: Tanshinone IIA; Compound label in the paper: T2A

Experimental findings for the reported parent compound and tested material; no validation of the current AdooQ lot or human efficacy.

Results Sec9; Fig. 7A–C (high-dose GBM59 comparison); Methods Sec13, Sec19–Sec20

Spheroid volume change at day 9: Fig. 7A–C image and caption; mean ± SEM, 3 biological repeats, 3 technical repeats each; two-tailed Mann–Whitney test. Exact volumes not transcribed. — Results Sec9; Fig. 7A–C; Methods Sec19–Sec20

NQO1-dependent cellular sensitivity

Cell-based study · Human NSCLC A549 and NCI-H596 cells; NQO1 perturbation controls [2]

In a 72-h MTT assay A549 cells were more sensitive than NQO1-negative H596 cells. Dicoumarol and NQO1 siRNA reduced A549 sensitivity; matched NQO1-expression versus vector controls supported NQO1 dependence. p53 inhibition or knockdown had little effect in this design. These model-dependent results do not establish a universal cytotoxic concentration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
A549 metabolic viability72-h MTT IC50 5.32 µM[2]
NQO1-negative H596 metabolic viability72-h MTT IC50 >40 µM[2]

Literature-Reported Treatment Conditions

Treatment concentration
TSA 0.4–40 µM for parental-cell dose response; matched-cell dose response extends to 80 µM in Fig. 1E
Exposure duration
72 h
Method
MTT endpoint; untreated control, pharmacological and gene-perturbation comparisons
Vehicle
Treatment vehicle composition not specified in Cytotoxicity assay method
Co-treatment
DIC 10 µM pretreatment for 30 min; NAC and p53 inhibitor/siRNA controls are distinct from single-agent IC50 assays
Reported limits
Treatment vehicle not established; MTT reports metabolic viability, not a direct cell-count endpoint; no uncertainty supplied for fitted IC50 values.
Methods and source locations

Compound reported in the paper: Tanshinone IIA; Compound label in the paper: TSA

Experimental findings for the reported parent compound and tested material; no validation of the current AdooQ lot or human efficacy.

Results s2a; Fig. 1A–F; Methods s4b–s4e, s4k, s4p

A549 metabolic viability: MTT; results s2a; Fig. 1 data mean ± SE of three independent experiments (not an IC50 error interval). — Results s2a; Fig. 1B; Methods s4e

NQO1-negative H596 metabolic viability: MTT; resistant comparator tested alongside A549. Operator retained as reported. — Results s2a; Fig. 1B; Methods s4e

Tanshinone IIA (Tanshinone B) In Vivo Studies

In A549 xenograft-bearing nude mice, tanshinone IIA (20 mg/kg intraperitoneally every other day) reduced tumor growth. At day 20, tumor volumes were 279±46 mm³ versus 552±90 mm³ with vehicle (mean ± SE; six mice per group). Dicoumarol pretreatment antagonized the response, supporting a role for NQO1 in this model. [2]

A549 xenograft growth and dicoumarol antagonism

Animal study · A549 tumor-bearing athymic nude mice, 6–8 weeks old; six mice per group [2]

TSA reduced tumor growth relative to vehicle. Dicoumarol pretreatment significantly antagonized this effect; dicoumarol alone also modestly inhibited growth. This is preclinical efficacy in one xenograft model, not a general safety or clinical efficacy demonstration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume after 20 daysMean ± SE; six mice/group TSA: 279±46 mm³; vehicle: 552±90 mm³; DIC alone: 439±99 mm³[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Every other day
Treatment course
3 weeks; tumor-volume comparison after 20 days
Vehicle
Full vehicle composition unspecified; TSA solid dispersion with PEG6000 described in Results
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle controlReference arm552±90 mm³ after 20 days[2]
TSA alone
TSA 20 mg/kg
Vehicle279±46 mm³ after 20 days; P<0.01 versus vehicle[2]
DIC alone
DIC 5 mg/kg
Vehicle439±99 mm³ after 20 days; described as slight growth inhibition[2]
DIC before TSA
DIC 5 mg/kg then TSA 20 mg/kg, 1 h later
TSA aloneDIC significantly antagonized TSA-mediated growth suppression (P<0.05); exact volume not transcribed[2]
Vehicle control
Model: A549 tumor-bearing athymic nude mice; n=6 per group
Reported limits: Mouse sex and complete vehicle composition not established in selected efficacy methods.
TSA alone
Model: A549 tumor-bearing athymic nude mice; n=6 per group
Reported limits: Mouse sex and complete vehicle composition not established in selected efficacy methods.
DIC alone
Model: A549 tumor-bearing athymic nude mice; n=6 per group
Reported limits: Mouse sex and complete vehicle composition not established in selected efficacy methods.
DIC before TSA
Model: A549 tumor-bearing athymic nude mice; n=6 per group
Reported limits: Mouse sex and complete vehicle composition not established in selected efficacy methods.
Methods and source locations

Compound reported in the paper: Tanshinone IIA; Compound label in the paper: TSA

Experimental findings for the reported parent compound and tested material; no validation of the current AdooQ lot or human efficacy.

Results s2f; Fig. 8A; Methods s4a, s4n, s4p

Tumor volume after 20 days: Caliper volume: length × width × width / 2; Results s2f reports P<0.01 for TSA versus vehicle. Fig. 8A gives P<0.05 for TSA versus TSA+DIC. No combination volume inferred. — Results s2f; Fig. 8A; Methods s4n

Vehicle control · Results s2f; Fig. 8A; Methods s4n

TSA alone · Results s2f; Fig. 8A; Methods s4n

DIC alone · Results s2f; Fig. 8A; Methods s4n

DIC before TSA · Results s2f; Fig. 8A; Methods s4n

Specifications

Manufacturer Adooq Bioscience
CAS Number 568-72-9
Formula C19H18O3
Molecular Weight 294.3
Synonyms Tanshinone B; Tanshinone II
SMILES
CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 4 mg/mL (13.58 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
0.1 mg/mL
Vehicle
5% DMSO+30% PEG 300+2% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Tanshinone IIA (Tanshinone B) Research References

  1. [1] Schaf J, Shinhmar S, Zeng Q, et al. Enhanced Sestrin expression through Tanshinone 2A treatment improves PI3K-dependent inhibition of glioma growth Cell death discovery (2023). PMID: 37202382 DOI: 10.1038/s41420-023-01462-6 Source material
  2. [2] Liu F, Yu G, Wang G, et al. An NQO1-initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancer PloS one (2012). PMID: 22848731 DOI: 10.1371/journal.pone.0042138 Source material

Publications

3 publications citing this product

  1. Qiwen Yan, .et al. , Regen Ther, 2023, Dec; 24: 417-425 PMID: 37727797
  2. Judith Schaf, .et al. , Cell Death Discov, 2023, May 19;9(1):172 PMID: 37202382
  3. Williams R, .et al. , Research Square, 2022, NOV 21

Added to your cart

View Cart Checkout
Loading...